Recombinant Human Cadherin-6 / KCAD / CDH6 Protein, His tag, 100µg

Background
Cadherin-6 (CDH6) also known as Kidney cadherin (K-cadherin or KCAD), is a a type II classical cadherin from the cadherin superfamily. Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. CDH6 / KCAD contains five cadherin domains. CDH6 is highly expressed in brain, cerebellum, and kidney. Lung, pancreas, and gastric mucosa show a weak expression and also expressed in certain liver and kidney carcinomas.

Source
Recombinant Human CDH6 /Cadherin-6 Protein, His Tag (CA6-H5229) is expressed from human 293 cells (HEK293). It contains AA Thr 19 - Ala 615 (Accession # AAH00019).
Predicted N-terminus: Thr 19 & Ser 54

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus. The Human Cadherin-6 will be further processed into mature form (Ser 54-Ala 615). The protein has a calculated MW of 67.2 kDa (pro-form) and 63.4 kDa (mature-form). The protein migrates as 86-96 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>85% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "The knockdown of stathmin with si-RNA inhibits invasion of mesothelioma"
Aksoy, Varoglu, Onalan et al
Tissue Cell (2024) 87, 102303
(2) "Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models"
Suzuki, Nagase, Saito et al
Mol Cancer Ther (2024) 23 (3), 257-271
(3) "Screening tumor stage-specific candidate neoantigens in thyroid adenocarcinoma using integrated exome and transcriptome sequencing"
Jia, Liang, Li et al
Front Immunol (2023) 14, 1187160
Showing 1-3 of 186 papers.